J 2021

NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats

RUDÁ, Jana, Petra AMCHOVÁ, Filip ŠIŠKA and Yousef TIZABI

Basic information

Original name

NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats

Name in Czech

NBQX snižuje relaps vyhledávání nikotinu, ale ne operantní příjem nikotinu či metamfetaminu u potkana

Authors

RUDÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Petra AMCHOVÁ (203 Czech Republic, belonging to the institution), Filip ŠIŠKA (703 Slovakia, belonging to the institution) and Yousef TIZABI (840 United States of America)

Edition

The World Journal of Biological Psychiatry, Abingdon, TAYLOR & FRANCIS, 2021, 1562-2975

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.418

RIV identification code

RIV/00216224:14110/21:00121323

Organization unit

Faculty of Medicine

UT WoS

000639904700001

Keywords in English

AMPA/kainate receptor; Nicotine; Methamphetamine; Self-administration; Relapse

Tags

Tags

International impact, Reviewed
Změněno: 21/2/2022 10:28, Mgr. Tereza Miškechová

Abstract

V originále

Pharmacological manipulations of glutamatergic ionotropic receptors have been suggested as a promising target for addiction treatment. Antagonists of AMPA/kainate receptors were shown to reduce alcohol intake or alcohol-seeking in various animal models. In this study, we evaluated the effect of NBQX, an AMPA/kainate receptor antagonist, on methamphetamine (METH) and nicotine self-administration in rats.

Links

MUNI/A/1249/2020, interní kód MU
Name: Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii (Acronym: SV_Farmakologie2021)
Investor: Masaryk University
MUNI/A/1292/2019, interní kód MU
Name: Preklinický a klinický výzkum studentů v oblasti farmakokinetiky, neuropsychofarmakologie a personalizované farmakoterapie v onkologii
Investor: Masaryk University, Category A